Trial · NCT07227779
BPaLMZ for TB Meningitis
NCT07227779, Phase 2, Recruiting, David Boulware
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. BPaLMZ for TB Meningitis. Trials, record NCT07227779. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07227779
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- BPaLMZ for TB Meningitis
- NCT number
- NCT07227779
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 312 participants, estimated
- Lead sponsor
- David Boulware
- Conditions
- Tuberculous Meningitis, HIV, Meningitis, TB - Tuberculosis
- Interventions
- BPaLMZ Regimen
- First posted
- 2025-11-13
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 24-week Survival | 24 Weeks | Survival Time |
| Primary | Hierarchical composite endpoint (survival time + functional status) | 24 Weeks | Hierarchical composite endpoint of survival time and Rankin score (0-5 scale) assessed by Win Ratio |
| Secondary | Serious adverse events (SAE) | 28 weeks | Incidience of Serious adverse events |
| Secondary | Clinical Adverse Events | 28 weeks | Clinical Adverse Events, by grade (1-5) associated with TB drug discontinuation, dose reduction, or interruption \>=3 days |
| Secondary | Laboratory abnormalities | 28 weeks | Number of participants with grade 3 or 4 abnormal laboratory values, by the Division of AIDS toxicity grading scale |
| Secondary | Neuropathy | 28 weeks | Incidence of Neuropathy |
| Secondary | Drug induced liver injury | 28 weeks | Drug induced liver injury with Grade \>=3 with serum alanine aminotransferase (ALT) \>5x upper limit or normal or total bilirubin \>2.5x upper limit of normal) |
| Secondary | Change in CSF inflammatory markers | 14 days | Change in CSF leukocytes from baseline to day 7 and 14 visits. |
| Secondary | Modified Rankin Scale | 24 weeks | Modified Rankin Score as an ordinal score (0-6 scale) of: 0 Alive: no residual symptoms or disability. 1. No significant disability: symptoms are present but do not prevent carrying out all usual duties and activities; able to carry out all pre-TBM activities. 2. Slight disability: unable to carry out all pre-TBM activities but able to look after self without daily help. 3. Moderate disability: requires some assistance with tasks but able to walk without assistance. 4. Moderately severe disability: unable attend to bodily functions or walk without assistance. 5. Severe disabilities: bedridden, incontinent, requires continuous care and attention. 6. Dead |
| Secondary | Change in blood inflammatory markers | 7 days | Change in white blood cell count from baseline to day 7 visit |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07227779
GET https://conductscience.org/api/trials/v1/NCT07227779/registered